figuring out the actual risk of COX-2 inhibitors

March 2005

Health Canada is getting closer to figuring out the actual risk of COX-2 inhibitors...and how to use them appropriately.

They will be adding new special warnings and dosage limits to the COX-2 inhibitors remaining on the market.

Vioxx might even come back in some countries. That's because now we know cardiovascular problems aren't unique to Vioxx...and it's the ONLY COX-2 so far that has proven GI benefits.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

figuring out the actual risk of COX-2 inhibitors
Are all inhalation devices equally effective
Cardiology concerns about Plavix and GI bleeding
abrupt market withdrawal of Adderall XR (mixed amphetamines)
new SSRI antidepressant called Cipralex
guidelines for treating migraines in CHILDREN
Cholesterol warning about new safety data on Ezetrol
HIV & AIDS new recommendations for preventing HIV immediately AFTER an exposure
Gastroenterology whether chronic use of stimulant laxatives is harmful
Gastroenterology Is it important for patients to avoid aspirin and NSAIDs before fecal occult blood tests (Hemoccult, etc)
Gastroenterology if drug doses need to be altered after gastric bypass surgery
Dermatology benzoyl peroxide often works as well as oral minocycline for mild to moderate facial acne
Diabetes new long-acting insulin called Lantus
Drug Testing People are asking about drug testing

figuring out the actual risk of COX-2 inhibitors

Practical advice for a better career, with unlimited access to CE

Table of Contents